

Application No. 09/902,460
Attorney's Docket No. 004973-078
Page 2

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) An A recombinant isolated DNA molecule encoding a mammalian FGF, which comprises a heparin binding domain and wherein said heparin binding domain wherein said mammalian FGF comprises substitution of one or more positively charged amino acid residues located in a heparin binding domain of at residues 128 through 138 with a neutral or negatively charged amino acid residue, and wherein the substitution of the one or more residues occurs in residues corresponding to residues 128 through 138 of human basic FGE.
2. (Currently Amended) The isolated DNA molecule of claim 1 which encodes a human FGF protein.
3. (Currently Amended) The isolated DNA molecule of claim 1 which encodes a human basic FGF protein.
4. (Currently Amended) The isolated DNA molecule of claim 3 which encodes a human basic FGF protein with reduced affinity for heparin binding.
5. (Canceled)
6. (Previously Presented) The isolated DNA molecule of claim 5, wherein the neutral or negatively charged amino acid is selected from the group consisting of serine, threonine or glutamic acid.
7. (Previously Presented) The isolated DNA molecule of claim 5,

Application No. 09/902,460
Attorney's Docket No. 004973-078
Page 3

wherein the location and composition of the substituted amino acid is selected from the group consisting of serine₁₂₈, glutamic acid₁₂₈, threonine₁₂₉, serine₁₂₈/threonine₁₂₉, and serine₁₃₈.

8-14. (Canceled)

15. (Previously Presented) The isolated DNA molecule of claim 3 which is operably linked to control sequences for expression.

16. (Previously Presented) The isolated DNA molecule of claim 15, wherein the control sequences include a transcription termination signal.

17. (Previously Presented) The isolated DNA molecule of claim 3 which is transformed into a recombinant host cell.

18. (Currently Amended) A recombinant vector containing the isolated DNA molecule of claim 3 and effective in expressing said human basic FGF.

19. (Withdrawn) The vector of claim 18 which is selected from the group consisting of plasmids pUC9-TSF11 and pUC9delH3-pTSF-3.

20. (Previously Presented) The vector of claim 18, wherein the isolated DNA molecule encoding an FGF is operably linked to control sequences compatible with bacteria.

21. (Currently Amended) The vector of claim 18, wherein the isolated DNA molecule encoding the human basic an FGF is operably linked to control sequences compatible with mammalian hosts.

22. (Withdrawn) Recombinant host cells transformed with the

Application No. 09/902,460
Attorney's Docket No. 004973-078
Page 4

vector of claim 18.

23. (Withdrawn) Bacterial cells transformed with the vector of claim 20.

24. (Withdrawn) Mammalian cells transformed with the vector of claim 21.

25. (Currently Amended) A method for producing a human basic FGF protein which comprises culturing host cells harboring the DNA of claim 3 and recovering the human basic FGF protein.

26. (Previously Presented) The method of claim 25, wherein the host cells are bacterial.

27. (Previously Presented) The method of claim 25, wherein the host cells are mammalian.

28-32. (Canceled)